Self-assembling Bisphosphonate Nanocomplexes for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bisphosphonate formulations, such as zoledronic acid, face challenges in achieving direct anti-cancer activity due to rapid elimination and accumulation in bones, limiting their effectiveness in treating tumors, and existing nanotechnology-based formulations suffer from stability issues and low encapsulation efficiency.
Innovation Solution
Development of nanocomplexes comprising bisphosphonates complexed with calcium and phosphate salts mixed with liposomes, which are self-assembling nanoparticles with a mean diameter ranging from 10 to 500 nm, allowing for high drug loading and improved pharmacokinetic profiles, and the option to add targeting ligands for specific cancer cell targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If zoledronic acid is administered intravenously, then rapid elimination and bone accumulation occur, but direct anti-cancer activity is limited due to low plasma concentration
Solution Approach 1:
The patent uses liposomes as intermediary carriers to transport zoledronic acid from the bloodstream to tumor cells. The liposomal encapsulation protects the drug during circulation and enables targeted delivery through receptor-mediated endocytosis, thereby achieving effective anti-cancer concentrations without requiring high systemic plasma levels
Solution Approach 2:
The patent modifies the pharmacokinetic parameters of zoledronic acid by formulating it in liposomes. This changes the drug's distribution profile, extending circulation half-life and enabling accumulation in tumor tissues through the enhanced permeability and retention effect, thereby achieving therapeutic concentrations at the target site without increasing systemic exposure
2Reliability
If stealth liposomes are used to deliver zoledronic acid, then tumor growth reduction is achieved, but physical stability is reduced requiring lyophilization
Solution Approach 1:
The patent applies preliminary protective action by incorporating lyophilization (freeze-drying) as a stabilization step. The liposomal formulation is frozen and dried under controlled conditions before storage, creating a stable solid state that prevents degradation during storage and transport, while maintaining the encapsulated drug's bioactivity for subsequent reconstitution and administration
3Quantity of substance
If zoledronic acid is encapsulated in liposomes, then encapsulation efficiency is low at about 5%, but drug loading can be improved with new formulations
Solution Approach 1:
The patent optimizes encapsulation parameters including lipid composition ratios, cholesterol content, hydration temperature, and sonication conditions. These parameter adjustments enhance the liposomal membrane's capacity to incorporate zoledronic acid during preparation, thereby improving both encapsulation efficiency and drug loading capacity while maintaining the stability and targeting functionality of the formulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanocomplexes demonstrate enhanced antitumor effects compared to previous formulations, with higher drug loading and stability, effectively inhibiting tumor growth and metastasis, and show complete regression of tumors in animal models, while being well-tolerated with no significant toxicity.
Implementation Method 1
self-assembling nanoparticles
Implementation Method 2
bisphosphonates complexed with calcium and phosphate salts
Data Source
Figure 1
Figure 2
AI summary
The present invention descrive nanocomplexes also called auto-assembling nanoparticles comprisingbiphosphonates, lipid nanovectors and inorganic nanovectors. In particular the invention describes zoledronic acid complexed with calcium phosphate base nanoparticles; said particles in their turn mixed with lipidic particles e.g. liposomes. Said nanocomplexes are useful, and showed to be be efficient in vivo, as pharmaceutical formulations of biphosphonates for the treatment or prevention of tumor growth and/or metastasis. Tumors can be solidsand/or haematological such as prostate, lung, head/neck, colon, liver, breast, pancreas, kidneys, bladder, male and female urogenital tract, bones, multiple myeloma, primitive and secondary tumours of the central nervous system and lymphomas.